Decernotinib

Decernotinib
Identifiers
	IUPAC name (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide;
CAS Number	944842-54-0;
PubChem CID	86322203;
ChemSpider	30843790;
UNII	MZK2GP0RHK;
KEGG	D10585;
CompTox Dashboard (EPA)	DTXSID70241504 ;
Chemical and physical data
Formula	C18H19F3N6O
Molar mass	392.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3;
	InChI InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1; Key:ASUGUQWIHMTFJL-QGZVFWFLSA-N;

Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It has been studied in clinical trials at Vertex Pharmaceuticals,^[1] and while it was not approved for clinical use it continues to be used for research.^[2]^[3]^[4]

References

^ Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, et al. (September 2015). "Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry. 58 (18): 7195–216. doi:10.1021/acs.jmedchem.5b00301. PMID 26230873.
^ Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, et al. (November 2020). "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research". RMD Open. 6 (3): e001374. doi:10.1136/rmdopen-2020-001374. PMC 7856126. PMID 33188136.
^ Rocha CM, Alves AM, Bettanin BF, Majolo F, Gehringer M, Laufer S, et al. (June 2021). "Current jakinibs for the treatment of rheumatoid arthritis: a systematic review". Inflammopharmacology. 29 (3): 595–615. doi:10.1007/s10787-021-00822-x. PMID 34046798.
^ Hu L, Liu R, Zhang L (October 2022). "Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors". International Immunopharmacology. 111: 109095. doi:10.1016/j.intimp.2022.109095. PMID 35926270.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, et al. (September 2015). "Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry. 58 (18): 7195–216. doi:10.1021/acs.jmedchem.5b00301. PMID 26230873.

[2] Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, et al. (November 2020). "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research". RMD Open. 6 (3): e001374. doi:10.1136/rmdopen-2020-001374. PMC 7856126. PMID 33188136.

[3] Rocha CM, Alves AM, Bettanin BF, Majolo F, Gehringer M, Laufer S, et al. (June 2021). "Current jakinibs for the treatment of rheumatoid arthritis: a systematic review". Inflammopharmacology. 29 (3): 595–615. doi:10.1007/s10787-021-00822-x. PMID 34046798.

[4] Hu L, Liu R, Zhang L (October 2022). "Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors". International Immunopharmacology. 111: 109095. doi:10.1016/j.intimp.2022.109095. PMID 35926270.

[1]

[2]

[3]

[4]